912934-76-0 Usage
Uses
Used in Pharmaceutical Industry:
3-Bromo-5-(2-chlorophenyl)-pyridine is utilized as an intermediate in the synthesis of pharmaceuticals, playing a crucial role in the development of new drugs. Its unique structure allows for the creation of a variety of complex molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-Bromo-5-(2-chlorophenyl)-pyridine serves as an intermediate in the synthesis of various agrochemicals, contributing to the development of effective products for crop protection and enhancement of agricultural yields.
Used in Medicinal Chemistry and Drug Discovery:
3-Bromo-5-(2-chlorophenyl)-pyridine is employed as a building block in medicinal chemistry and drug discovery due to its potential to form molecular probes. These probes are instrumental in understanding biological processes and identifying new therapeutic targets.
Used in Organic Reactions:
3-BROMO-5-(2-CHLOROPHENYL)-PYRIDINE is also used in organic reactions as a building block for the creation of complex molecules. Its reactivity and structural features make it a versatile component in organic synthesis, facilitating the development of novel organic compounds with diverse applications.
Check Digit Verification of cas no
The CAS Registry Mumber 912934-76-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,9,3 and 4 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 912934-76:
(8*9)+(7*1)+(6*2)+(5*9)+(4*3)+(3*4)+(2*7)+(1*6)=180
180 % 10 = 0
So 912934-76-0 is a valid CAS Registry Number.
912934-76-0Relevant academic research and scientific papers
POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Page/Page column 37, (2011/04/24)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
